

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Akums receives DCGI approval for type 2 diabetes drug to improve insulin resistance

06 February 2023 | News

The number of people with diabetes in India is the second highest in the world (74 million), after China (141 million)



Akums Drugs and Pharmaceutical has given a boost to the treatment of type 2 diabetes with the launch of the novel antidiabetic drug 'Lobeglitazone'. The drug, released by the company, is a new formulation manufactured specifically for type 2 diabetic patients by helping them improve pancreatic beta-cell function.

With this release, New Delhi-based Akums has become the first contract development and manufacturing organisation (CDMO) to launch Lobeglitazone tablets for commercial consumption.

The drug was formulated for type 2 diabetics who secrete insulin but have poor insulin sensitivity in their organs, making them less able to utilise insulin. Lobeglitazone is a one-of-a-kind medication which has a relatively low risk of hypoglycemia. The unique formulation was manufactured to improve insulin resistance rather than force its release from the pancreas.

Lobeglitazone is a film-coated tablet made up of Lobeglitazone Sulfate equivalent to Lobeglitazone at 0.5 mg. It is approved by the Drugs Controller-General of India (DCGI) and offers a number of advantages, including higher safety profile, higher effectiveness in lower dosage, lower risk of hypoglycemia, and improved pancreatic beta-cell function, among others.

The company also plans to introduce more fixed dose drug combinations (FDCs) in the future specifically for the treatment and management of diabetes.